



## Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, June 5<sup>th</sup>, 2025  
1:05 PM - 3:35 PM  
Via Zoom webinar

### MEETING MINUTES

---

**NOTE:** Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

**Members Present:** Stacy Ramirez, PharmD; Samara Stevens, ND; Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Eriko Onishi, MD; Eddie Saito, PharmD; Jeanne Savage, MD;

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Trevor Douglass, DC; Lan Starkweather, PharmD; Brandon Wells; Jennifer Bowen; Michael Yu, DC; Kyle Hamilton

**Audience:** Adrian Lau\*, J&J; Chad Duncan\*, Vertex; Mary Rebar\*; Greg Kichens, Artia Solutions; Reya Nematian, Advanced Health; Lewis Backus, OHA; Haylie Utzman, OSU PharmD Candidate; Lisa Pulver; Andy Berg, Audaire Health; Heidi Gullett, MD, OHA-HERC; Divine Marcelo, Amgen; Lynda Finch, Biogen; Tammi Ocumpaugh, Otsuka; Erin Nowak, AbbVie; Gary Parenteau, Dexcom; Mark Kantor, AllCare Health; April Grant, Vertex; Shauna Wick, Trillium; Jill Carroll; Chris Ferrin, IHN; Rosalie Elliott, Umpqua Health; Deron Grothe, Braeburn; Lisa Dunn; Aliethia McLeod, Trillium; T Shriner; Amy Breen, Teva; Brett Freund; Melissa Snider, Gilead; Erika Rosie; Bryan Armstrong, CareOregon; Levi Smith; Chris Johnson; Marissa Dunn; Norm Navarro; Kimberly Keller; Bryan Mauk

**(\*) Provided verbal testimony**

---

## I. CALL TO ORDER

- A. Roll Call & Introductions
  - Meeting called to order at approx. 1:05 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and April Minutes presented by Roger Citron, RPh
  - ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**
- D. Department Update provided by Andrew Gibler, PharmD

---

## II. CONSENT AGENDA TOPICS

- A. **Quarterly Utilization Report**
- B. **Oncology Prior Authorization (PA) Updates**  
**Recommendation:**
  - Add: Datroway® (datopotamab deruxtecan-dlnk) to Table 1 in the Oncology Agents PA criteria
- C. **Orphan Drug Policy Updates**  
**Recommendation:**
  - Update Table 1 in the Orphan Drugs PA criteria to support medically appropriate use of Niktimvo™ (axatilimab-csfr); Vykat™ XR (diazoxide choline); and Ryoncil® (remestemcel-L-rknd) based on their FDA-approved label**ACTION: Motion to approve, 2nd, all in favor**

---

## III. DUR ACTIVITIES

- A. **ProDUR Report:** Lan Starkweather, PharmD
- B. **RetroDUR Report:** Dave Engen, PharmD
- C. **Oregon State Drug Review:** Kathy Sentena, PharmD
  - 1. **New and Emerging Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic DysfunctionAssociated Steatohepatitis (MASLD/MASH) in Adults**
  - 2. **Update on the Biosimilar Landscape in the United States Market**
  - 3. **Review of Off-Label Use of Gabapentin and Pregabalin**

---

## IV. NEW BUSINESS

- A. **Actinic Keratosis(AK) Class Review:** Deanna Moretz, PharmD  
**Recommendation:**
  - Add "Topical Agents for Actinic Keratosis" class to the PDL
  - Make preferred at least one topical formulation of 5-FU and imiquimod - indicated to treat basal cell carcinoma and genital warts
  - Maintain diclofenac 3% gel as non-preferred and add tirbanibulin 1% ointment and aminolevulinic acid gel as non-preferred
  - Implement PA criteria for topical agents used in AK to provide a pathway to coverage for AK in people with the EPSDT benefit.
  - Evaluate costs in executive session**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**
- B. **Egrifta SV® (tesamorelin) PA Update:** Deanna Moretz, PharmD  
**Recommendations:**
  - Revise Tesamorelin PA criteria to define medical necessity and appropriateness for patients eligible for coverage under Early Periodic Screening Diagnostic and Treatment (EPSDT)**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

**C. Drugs for Dry Eye Disease: Kathy Sentena, PharmD**

**Recommendations:**

- Create a "Drugs for Dry Eye" PDL class
- Make all prescription products for the treatment of dry eye and vernal keratoconjunctivitis non-preferred based on the evidence
- Implement PA criteria to provide a pathway for coverage for therapies for vernal keratoconjunctivitis, for patients with comorbidities which allow for funding of dry eye, or who qualify under EPSTD
- Evaluate comparative costs in executive session

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**D. Spravato® (esketamine) Prior Authorization Update and Drug Use Evaluation: Sarah Servid, PharmD**

**Recommendations:**

- Update PA criteria to clarify documentation required to support diagnosis and permit monotherapy with esketamine in people with treatment-resistant depression

**Public Comment:** Adrian Lau, Johnson & Johnson

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**E. Journavx™ (suzetrigine) New Drug Evaluation: Sara Fletcher, PharmD**

**Recommendations:**

- Implement PA as proposed including use beyond 48 hours and limit use to no more than 14 days

**Public Comment:** Chad Duncan, Vertex; Mary Rebar

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**F. Topical Drugs for Molluscum Contagiosum: Dave Engen, PharmD**

**Recommendations:**

- Create a new PDL class for agents to treat molluscum contagiosum
- Add cantharidin topical solution 0.7% (Ycanth®) and berdazimer gel 10.3% (Zelsuvmi™) to the Molluscum Contagiosum Drugs PDL class
- Implement PA criteria for cantharidin and berdazimer to define medical necessity under EPSTD

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**

**G. Nutritional Supplements PA Update: Sara Fletcher, PharmD**

**Recommendations:**

- Add coverage for oral solid dosage forms, powders, and concentrated liquids of nutritional supplements for people with inborn errors of metabolism
- implement the proposed Nutritional Supplements as Prescribed Drugs for Special Conditions PA criteria to limit coverage to specific nutritional supplements based on current standards of care for those eligible under EPSTD

**ACTION: Motion to approve, 2<sup>nd</sup>, all in favor**



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy Phone 503-947-5220 | Fax 503-947-1119

**H. Nuedexta® (dextromethorphan/quinidine) New Drug Evaluation:** Deanna Moretz, PharmD

**Recommendations:**

- Implement PA criteria for dextromethorphan/quinidine to define medical necessity under EPSDT
- Maintain dextromethorphan 20 mg/quinidine 10 mg as nonpreferred on the PDL

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

---

**V. EXECUTIVE SESSION**

**Members Present:** Bridget Bradley, PharmD; Douglas Carr, MD; Patrick DeMartino, MD; Russ Huffman, PMHNP; Cat Livingston, MD; Jeanne Savage, MD; Samara Stevens, ND

**Staff Present:** Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Kyle Hamilton

---

**VI. RECONVENE for PUBLIC RECOMMENDATIONS**

**A. Actinic Keratosis**

**Recommendation:** Make 5% imiquimod cream and 5% 5-FU cream preferred. Make all other product non-preferred

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

**B. Drugs for Dry Eye Disease**

**Recommendations:** Make all products non-preferred

**ACTION:** Motion to approve, 2<sup>nd</sup>, all in favor

---

**VII. ADJOURN**